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A pressing concern in the SARS-CoV-2 epidemic and other viral outbreaks, is the extent to
which the containment measures are halting the viral spread. A straightforward way to assess
this is to tally the active cases and the recovered ones throughout the epidemic. Here, we
show how epidemic control can be assessed with molecular information during a well
characterized epidemic in Iceland. We demonstrate how the viral concentration decreased in
those newly diagnosed as the epidemic transitioned from exponential growth phase to
containment phase. The viral concentration in the cases identified in population screening
decreased faster than in those symptomatic and considered at high risk and that were
targeted by the healthcare system. The viral concentration persists in recovering individuals
as we found that half of the cases are still positive after two weeks. We demonstrate that
accumulation of mutations in SARS-CoV-2 genome can be exploited to track the rate of new
viral generations throughout the different phases of the epidemic, where the accumulation of
mutations decreases as the transmission rate decreases in the containment phase. Overall,
the molecular signatures of SARS-CoV-2 infections contain valuable epidemiological infor-
mation that can be used to assess the effectiveness of containment measures.
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The fact that 135 million individuals (as of 11 April 2021)have been infected by the SARS-CoV-2 virus worldwide1underscores the explosive spread of the COVID-19 pan-
demic in part due to the inadequacy of the global infrastructure to
deal with highly contagious pathogens. The first case of COVID-
19 was diagnosed in Iceland on February 28, the largest number
of active infections was on April 4th and on May 5th the first
phase of the epidemic was all but over (Fig. 1). The key con-
tainment measures used by the authorities were to screen widely
for the virus, put those infected in isolation, and track their
contacts who were subsequently put in quarantine. The screening
for SARS-CoV-2 was done in three ways, (1) those targeted by the
healthcare system with signs and symptoms of disease or coming
back from high-risk areas such as the ski resorts of Italy and
Austria, (2) those who accepted an invitation to free screening,
and (3) a random sample from the population. The total number
of cases identified in the screenings was 1813 as of June 24. Most
of the cases could be traced to a preexisting case through contact
tracing. In Iceland, patients with confirmed SARS-CoV-2 infec-
tion were put in isolation for at least 2 weeks, and to be declared
recovered they had to be symptom-free for a week.
During a SARS-CoV-2 infection, the virions infiltrate the host’s
cells and start replication of their genomes and sub-genomic
products2, and the viral concentration increases rapidly after
infection as assessed with qPCR3–5. Then after the onset of
symptoms, the viral concentration starts to decrease3–5. The
mutations carried by virions from the transmitting host are
passed to the receiving host and can be used to track the spread of
the virions6–11. This means that there is substantial epidemiolo-
gical information in the viral concentration and sequence diver-
sity of SARS-CoV-2 infection. Here, we screened 63,701
nasopharyngeal samples and sequenced the virus from nearly all
1813 confirmed cases in Iceland. The sequence data in conjunc-
tion with the viral concentration allowed us to determine whether
this phase of the epidemic was on the rise or waning when
samples were collected. Having means to determine where an
epidemic such as COVID-19 is in its trajectory is useful for the
management of containment efforts.
Results
RNA viral concentration as a yardstick in an epidemic. The
number of SARS-CoV-2 cases in Iceland grew rapidly until the
end of March when the effect of measures to slow the spread of
the virus had materialized (Fig. 1). A total of 1813 cases had
tested positive as of June 24 with a qRT-PCR test from naso-
pharyngeal and oropharyngeal samples12. Of the 1813 cases, 1631
were diagnosed by the healthcare system while 182 were diag-
nosed through population screening (Fig. 2A).
We used two methods to assess viral concentration in tested
individuals: the cycle threshold (CT) values to detect a PCR
product from the qPCR test and the fraction of sequence reads
that mapped to the SARS-CoV-2 reference from viral RNA
sequencing. Both showed the concentration in newly diagnosed
cases decreases as the effect of the containment measures set in.
The qRT-PCR test provides a measure of viral concentration;
the higher the viral concentration the fewer cycles of PCR
amplification are needed to detect the virus13. The number of
PCR cycles required to detect the virus was available for 1667 of
the individuals who tested positive in Iceland. The qRT-PCR
experiments were performed at Landspitali University Hospital
(LUH) (E-gene probe) and deCODE genetics (ORF1ab, S and N
gene probes) with 238 samples being tested at both facilities. The
measurements at the two sites were highly correlated (Pearson’s
correlation ρ= 0.93; 95% CI: 0.91–0.95; Supplementary Fig. 1A).
For the subsequent analysis, we averaged the CT measurements
per individual for the samples with measurements at both
facilities. The number of PCR cycles needed to detect the virus
increased by 0.44 per week (95% CI: 0.24–0.64), interestingly, the
number of cycles needed to be increased faster in the population
screened individuals than in the ones targeted by the healthcare
system (Fig. 2B, 0.91 95% CI: 0.66–1.16 cycle per week and 0.30
95% CI:−0.10–0.51 cycle per week, respectively). The sympto-
matic individuals targeted by the healthcare system were probably
closer to the peak of their viral concentration, whereas individuals
identified in the population screening were likely recovering from
an asymptomatic or mildly symptomatic infection. To assess
whether we could replicate the temporal decay in the viral
concentration during the recovery phase in samples from other
populations, we reanalyzed the qRT-PCR data from a contained
epidemic in Australia11. In agreement with the Icelandic data, we
found that the viral concentration decreased (1.04 cycle per week
95% CI: 0.72–1.36) as the epidemic in Australia was contained
(Supplementary Fig. 2).
To assess how long the viral concentration persists in
individuals deemed recovered, we invited those who had tested
positive and had finished mandatory isolation to be qRT-PCR
tested again. A total of 1144 recovered individuals gave additional
samples between 10 and 81 days after first testing positive
(Fig. 3A). Of those who still tested positive on the second test, 263
had a third test at least 7 days after the second test. In total
1407 samples were tested of which 364 were positive (26%), 981
were negative (70%), and 62 undetermined (4%). Of the 1144
participants, 1136 had at least one determinable test result. The
fraction of individuals who tested positive halved every 13.3 days
(95% CI: 12.3–14.1 days, Fig. 3B). Including the undeterminable
samples in the analysis had a minimal effect; the number of
individuals not testing negative halves every 13.7 days (95% CI:
12.5–14.1 days, Supplementary Fig. 3).
We sequenced viral RNA from 1782 out of 1813 SARS-CoV-2
cases in Iceland and of those 1507 have at least 90% of the SARS-
CoV-2 reference genome covered by five or more reads. It may be
assumed that the fraction of reads mapping to the SARS-CoV-2
reference increases with the amount of viral RNA in the sample
and therefore the viral concentration. The fraction of mapped
reads decreased with time during the epidemic (4.6%, 95% CI:
Fig. 1 The molecular assessment of the Icelandic SARS-CoV-2 epidemic.
The number of infected and recovered individuals by date annotated with
molecular markers of SARS-CoV-2 epidemic.
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5.7%–3.5% per week; Fig. 2C; Supplementary Fig. 1). This is in an
agreement with the qRT-PCR results as the decrease indicates
that individuals sampled later in the epidemic had lower viral
concentration. The fraction of mapped reads decreased faster in
the population screened individuals (9.0%, 95% CI: 10.3–7.6% per
week) than the ones targeted by the healthcare system (3.5%, 95%
CI: 4.6–2.4% per week).
SARS-CoV-2 mutations provide a molecular signature of
containment. The rate of accumulation of mutations can be
estimated by comparing the mutations that have accumulated in
the sample from the root of the evolutionary tree of the virus to
the date of the viral sample collection14. The accumulation rate of
mutations is not only dependent on the mutation rate per viral
replication but can also be affected by the number of virions,
selection, and the length of the transmission interval.
The viral transmission consists of the initial population of
virions from the transmitting host that proliferates in the
receiving host. This transmission bottleneck is responsible for
the fact that viruses primarily accumulate mutations when they
are transmitted between people15. However, the possibility
certainly exists that mutations that occur when the virus
replicates within individuals may be detected if viral samples
are taken from the same individual at multiple time points.
Hence, we sequenced the virus from 203 retested individuals who
Fig. 2 The Icelandic SARS-CoV-2 epidemic. A Number of SARS-CoV-2-positive samples by time. B qPCR-CT values as a function of sampling date and
sample source. The number of samples in the population screening bins is 45, 8, 32, 53, 11, and 8 ordered by date. The number of samples in the targeted
screening bins is 34, 72, 202, 440, 454, 248, 53, and 5 ordered by date. C Fraction of SARS-CoV-2 reads mapping to reference as a function of sampling
date and sample source. The center values in error bars and bands are means. The error bars and bands are 95% CIs.
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had contracted COVID-19 and recovered from it. Only six of
these samples (2.9%) yielded adequate sequence coverage of the
SARS-CoV-2 genome. These six samples were taken >21 days
after the initial sample and in none of them did we detect
accumulation of mutations in the recovery phase, in agreement
with results from Australia11. This suggests that the two main
factors that could affect the rate of accumulation of mutations in
our analysis are the length of time between viral transmissions
and the time from infection to sample collection, both of which
are likely to be longer when the epidemic is declining.
To estimate the accumulation rate of SARS-CoV-2 mutations
per week, we regressed the number of mutations per viral genome
on sampling date. The number of viral mutations that were found
outside Iceland before 31st of March remained stable in the
Icelandic population (0.05 mutation accumulated per week, 95%
CI: 0–0.15), whereas the number of mutations that were rare in
GISAID (fewer than 10 copies) accumulated at a rate of 0.18
mutations per week (95% CI: 0.12–0.23). This demonstrates that
in Iceland, the accumulation of mutations was mostly due to local
transmissions in Iceland. Interestingly, the accumulation rate in
Iceland was lower than the accumulation rate derived from the
public GISAID data (0.50 mutations per week; 95% CI: 0.48–0.52;
Fig. 4A, B). Further, in Iceland, the rate of accumulation of
mutations was substantially greater for the first 3 weeks (0.34
mutations per week, 95% CI: 0.18–0.47), than for the subsequent
4 weeks (0.10 mutations per week, 95% CI: 0.02–0.18; Fig. 4A).
The slower rate of accumulation of mutations in the latter part of
the epidemic in Iceland indicates that the generation time of
infections was increasing or that SARS-CoV-2 cases had been
infected for longer when first detected.
Modeling the COVID-19 pandemic. The higher CT values, the
decreasing fraction of mapping sequence reads, and the reduction
in the accumulation of mutations indicate that the individuals
diagnosed late in the epidemic had been carrying the virus for
longer than those diagnosed early, although we acknowledge that
other scenarios are compatible with the data. As the viral gen-
erations of positive samples are unknown we modeled the con-
tainment in Iceland in an epidemiological model that tracks the
viral generation of positive samples in Iceland and incorporates
the observed molecular traces of SARS-CoV-2 infection. To
model this prolonged detection of SARS-COV-2 viral RNA, we
considered an extension of the susceptible, infected, and recov-
ered (SIR) epidemiological model, which allows modeling of the
spread of a disease in a closed population16. We extended this
model to record the number of viral generations and included a
state (SIPR model, Fig. 5A; Supplementary Fig. 4) with P repre-
senting recovered individuals who still test positive for the virus
but are not infectious, and thereby do not contribute to new viral
transmissions. In this model, kappa controls the rate of transition
from the positive (P) to recovered (R) states. We selected the
following parameters for the SIPR model, initial susceptible
population size (S0= 350000), initial infected population size
(I0= 100), initial infection rate (α= 0.197/S0) and recovery
rate (β= α /2) that fit the Icelandic outbreak with an initial rapid
growth that was then halted by containment measures (αc= α/10).
If the transition from a positive to a negative state is fast (kappa
much >1) then the model is close to the SIR model. However, in
the case of SARS-CoV-2, the rate of transition is slow (kappa
much <1), the fraction of infectious individuals among positive
individuals decreases rapidly after containment. Kappa mostly
affects the observed accumulation of mutations after the con-
tainment measures, reflecting that samples from older viral gen-
erations still test positive (Fig. 5B). We next assessed the effect of
the containment measures on the accumulation of mutations by
varying the strength of the containment measure and fixing kappa
at 0.5 (Fig. 5C). To reduce the accumulation of mutations by 30%
within 28 days, 76% reduction in the number of viral generations
is needed according to the SIPR model (black line in Fig. 5C). In
other words, the observed decrease in the mutation accumulation
rate as the epidemic progressed suggests the Icelandic measures
decreased the rate of new viral generations by an order of
magnitude.
Discussion
One of the difficult challenges in managing containment efforts in
an epidemic such as COVID-19 is to figure out at specific points
in time where the epidemic is in its trajectory, is gaining or
waning? In the work presented here, we show how changes in the
viral concentration and in the accumulation of viral mutations
can be used to determine the phase of the epidemic instead of
simply counting new cases.
Fig. 3 Molecular traces of SARS-CoV-2 recovery. A The number of days
separating the initial positive sample and the sample collected after
recovery. B The fraction of individuals that remained positive as a function
of days from the initial positive test.
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We estimated the viral concentration in two ways, with both
methods we show how the viral concentration decreases as the
epidemic wanes. However, whether the molecular traces of SARS-
CoV-2 infections detected in samples with high CT values
represent active virions or molecular remnants, is an open
question. In Iceland, the individuals classified as recovered who
still tested positive and had high CT values can shed some light
on this. After 364 of these recovered individuals left isolation, we
did not see a resurgence of COVID-19 cases indicating that these
individuals did not have sufficient viral concentration to infect
others and highlight the importance of prioritizing containment
measures of COVID-19 cases based on the viral concentration.
Viruses mainly accumulate mutations when they are transmitted
between people. Hence, the accumulation of mutations can be
used to assess the rate of transmissions. Furthermore, by esti-
mating the rate of accumulation of mutations during the SARS-
CoV-2 epidemic in Iceland, we demonstrate that in a rapidly
spreading viral epidemic, the time from infection to sample col-
lection is shorter than in an epidemic that has been slowed down
and the time between transmissions is longer. This demonstrates
that the mutation accumulation rate per week gives information
about how fast the epidemic is spreading and can provide a
quantitative assessment of the effectiveness of the measures taken
to slow down the spread of the virus. In this interpretation, we
assume that the time within an individual from initial infection to
being infectious stays the same throughout the epidemic.
Our results suggest that the accumulation of mutations per
week can be modeled as the product of the number of trans-
missions per week and the mutation accumulation rate per
transmission. In our analysis, we have assumed the accumulation
of mutations per transmission is constant throughout the epi-
demic. Stricter procedures in the containment phase could
decrease the number of virions in the initial population of
infection, which in turn could increase the probability of mutated
virions reaching fixation in the next host, resulting in a higher
mutation accumulation per transmission in the containment
phase. Therefore, future research is warranted in estimating the
effect of containment on the accumulation of mutation per
transmission.
We quantified the change in the viral concentration and accu-
mulation of mutations as the epidemic progressed. We believe that
standardization of molecular markers across laboratories would
enable inter-cohort comparison to better estimate the current status
of an outbreak rather than waiting for changes within the cohort to
occur. The correlation between the reduced accumulation of
mutations and the reduced viral concentration could be used to
standardize viral concentration values across cohorts, by comparing
the viral concentration of samples between cohorts with similar
numbers of mutations.
Methods
Ethics statement. The study was approved by the National Bioethics Committee
of Iceland (approval no. VSN-20-070). Samples were taken from individuals after
receiving informed consent from them or their guardians.
Population screening and targeted testing. We applied three previously
described approaches7 to detect SARS-CoV-2 infected individuals, briefly by tar-
geted testing of individuals traveling from high-risk areas or been exposed to an
infected individual; population screening of individuals, by offering people SARS-
CoV-2 test free of charge and through sending an invitation by text message to a
random subset.
Sample collection. For SARS-CoV-2 testing, nasopharyngeal and oropharyngeal
samples were taken using collection swabs, either Sigma VCMTM Duo ENT or
Sigma Transwab® ENT. RNA from all samples was isolated within 24 h.
RNA extraction. Viral RNA samples were extracted either at the Department of
Clinical Microbiology laboratory at Landspitali, the National University Hospital of
Iceland (LUH), or at deCODE. Both extraction methods are based on an auto-
mated magnetic bead-purification procedure, which includes cell lysis and Pro-
teinase K treatment. RNA from samples at LUH were extracted (32 samples per 60
min run) using the MagNA Pure LC 2.0 or MagNA Pure Compact instruments
from Roche LifeScience, with 200/100 µL input/output volume(s), respectively.
Samples at deCODE were extracted from swabs (96 samples per 70 min run) using
the Chemagic Viral RNA kit on the Chemagic360 instrument from Perkin Elmer,
Fig. 4 Accumulation of SARS-CoV-2 mutations. A Number of Icelandic private mutations as a function of the sampling date. The number of samples in the
bins is 20, 55, 225, 400, 388, 171, 43, and 7 ordered by date. B Number of mutations per sample that differ from the SARS-CoV-2 reference genome in the
GISAID data as a function of the sampling date. The number of samples in the bins are 21, 8, 15, 85, 262, 226, 149, 171, 239, 1112, 2420, 4699, 6394, 8168,
6611, 4917, 4332, 3462, and 2676 ordered by date. The error bars are 95% CIs and the center values are means.
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with 300/100 µL input/output volume(s), respectively. Each step in the workflow
was monitored using an in-house LIMS (VirLab) with 2D barcoding (Greiner,
300 µL tubes) of all extracted samples. MS2 bacteriophage RNA was added
(2.5% vol) for all samples subsequently assayed with Method 2 (see below).
All extracted RNA samples were stored at −80°C until further use.
Testing of samples for SARS-COV-2 using qRT-PCR. Testing for SARS-CoV-2
was performed either at LUH or deCODE using similar quantitative real-time
reverse transcription PCR (qRT-PCR) methods. The assay at LUH is based on the
WHO-recommended screening method (https://www.who.int/docs/default-source/
coronaviruse/wuhan-virus-assay-v1991527e5122341d99287a1b17c111902.pdf),
which involves a single probe pan-screening assay for betacoronaviruses, followed
by confirmatory measurements for all positive samples using a nCoV-2019-specific
assay. The broad betacoronavirus assay is based on probes for a conserved region of
the E-gene, whereas confirmatory testing assays were done using either nCoV-2019
specific probes for the RdRp gene or the TaqManTM Fast Virus 1-step Master Mix,
2019-nCoV Assay kits v1 from Thermo Fisher (see Method 1 below for details).
All labeled probes and primers for the E-and -RdRP genes were from TAG
(Copenhagen, Denmark). SuperscriptTM III One-Step RT-PCR assay mix with
PlatinumTM Taq DNA polymerase was from Thermo Fisher. 2019 E-gene
control and SARS-CoV Frankfurt 1 positive controls were obtained from EVAg
(https://www.european-virus-archive.com/bundle/diagnostics-controls-wuhan-
coronavirus-2019-2019-ncov). Each assay was done in a 25 µL total sample volume
with FAMTM dye-labeled probes in addition to VICTM dye-labeled probes for
human RNase P as an internal control. Plates (96 well) were scanned in an AB-
7500 Fast real-time PCR thermocycler for 40 cycles of amplification following the
manufacturer’s instructions (Thermo Fisher). Samples in the E-gene screening
assay with Ct < 35 were considered strong positive and went for confirmatory
testing using RdRp, whereas samples with Ct values between 35 and 37 were
considered weak positive and were confirmed using the TaqManTM Fast Virus
method. Samples with Ct values from 37 to 40 were classified as inconclusive and
were tested again to confirm their status.
SARS-CoV-2 screening at deCODE was performed using qRT-PCR assays in
either a singleplex (Method 1) or a multiplex (Method 2) format, respectively.
Method 1 uses the three probe TaqManTM Fast Virus 1-step Master Mix, 2019-
nCoV Assay kits v1, and 2019-nCov control kit from Thermo Fisher. Assay mix A,
B, and C were prepared to contain FAMTM dye-labeled probes for the SARS-CoV-
2-specific genes ORF1ab, S-gene, and N-gene, respectively. In addition, each assay
mix contained VICTM dye-labeled probes for human RNase P as internal control.
Samples from 96-well RNA sample plate(s) were dispensed into three wells each in
a 384 plate layout, in addition to three negative (no template) and three positive
controls. Assay mix was added in a total reaction volume of 12.5 µL per sample. All
sample aliquoting and mixing were performed with an automated Hamilton
STARlet 8-channel liquid handler and the assay plates were scanned in an ABI
7900 HT RT-PCR system following the manufacturer’s instructions with a total of
Fig. 5 Susceptible, infected, positive, and recovered epidemiological model. A schematic view of the flow of individuals in the epidemiological model. The
susceptible individuals are infected by individuals in different infection generations (I0 … In). These individuals then recover from the symptoms but test
positive (P0 … Pn). In the last stage, the positive individual’s transition to the recovered and negative state (R). See Supplementary Fig. 4. B Number of
individuals in each state S, I, P, and R by time. I and P represent the aggregation of the generation states. The bottom panel portrays the number of viral
generations by time. C The effect of containment measures on the number of viral generations.
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40 cycles of amplification. Samples with FAMTM dye Ct values <37 in at least two
of three assays were classified as positive. Samples with FAMTM dye Ct values
between 37 and 40 were classified as inconclusive and their testing repeated. If
repeated testing gave the same result with at least two probes the sample was
classified as positive. If repeated testing gave positive results for only one probe the
test was considered inconclusive and a new sample from the subject was requested.
The frequency of inconclusive results was 0.04%. Samples with undetected FAMTM
dye Ct values or values equal to 40 in all three assays were classified as negative if
the human RNase P assay was positive (VICTM dye Ct < 40). The sensitivity of the
assay was evaluated by serial dilution of the positive control and was estimated at 6
copies per reaction (Supplementary Table 1).
Method 2 uses the TaqPathTM COVID-19 CE-IVD RT-PCR kit from Thermo
Fisher (Catalog# A48067). TaqPathTM COVID‑19 is a multiplexed assay that
contains three primers/probe sets specific to different SARS-CoV-2 genomic
regions and primers/probes for bacteriophage MS2 as a control, all measured in the
same reaction well. The SARS-CoV-2 targets are the same as in Method 1, however,
each target and the MS2 control contain probes with different reporter dyes
(ORF1ab, FAMTM; N-gene, VICTM; S-gene, ABYTM; MS2, JUNTM). The MS2 was
used as an internal control and was added to each viral swab sample to assess the
efficacy of the sample preparation. All reactions were performed in a 384-well plate
layout in a total reaction volume of 6.25 µL per sample using an eight-channel
Hamilton STARlet liquid handler for dispensing and mixing. A negative control
(no template) and positive control (COVID-19 Control, 25 copies/reaction) were
run on each plate. Assay plates were scanned in an Applied BiosystemsTM 7500
Real-Time PCR instrument following the manufacturer’s instruction to a total
of 40 cycles of amplification. Result criteria were the same as described for
Method 1 above.
Sample preparation for sequencing. We used reverse transcription (RT) and
multiplex PCR to generate cDNA from the RNA samples, we based our setup on
information provided by the Artic Network initiative (https://artic.network/).
Briefly, we pre-incubated extracted RNA at 65°C for 5 min in the presence of
random hexamers (2.5 µM) and dNTP’s (500 µM), we then cooled the sample.
After cooling we performed RT using SuperScript IV (Thermo Fisher) in the
presence of DTT (5 mM) and RNaseOUT inhibitor (Thermo Fisher) for 10 min at
42°C, followed by 10 min at 70°C. We next amplified the resulting cDNA using a
multiplex PCR with a tiling scheme of primers. This scheme was designed to
generate overlapping amplicons of approximately 800 bp (Supplementary Data 1).
We split the primer pairs into two primer pools A and B, we then performed PCR
reaction per sample and primer pool (Supplementary Data 1). We performed PCR
amplification using the Q5® Hot Start High-Fidelity polymerase (New England
Biolabs) with primers at 1 µM concentration. We performed the thermal cycles in
an MJR machine with a heated lid at 105°C, using 35 cycles of denaturation (15 s at
98°C) and annealing/extension (5 min at 65°C). We then purified the resulting PCR
amplicons using Ampure XP magnetic beads (Beckman Coulter). Further, we
quantified the purified PCR amplicons using the Quant-iTTM PicoGreen dsDNA
assay kit (Thermo Fisher). We next randomly sheared the amplified samples
(20–500 ng) to construct sequence libraries. The shearing was performed by
focused acoustics in 96-well AFA-TUBE-TPX plates (Covaris Inc.) on the Covaris
LE220plus machine with the parameters: sample volume, 50 µL; temperature, 10°C;
peak incident power, 200W; duty factor, 25%; cycles per burst, 50; time, 350 s. We
used the fragmented cDNA to construct sequencing libraries in 96-well Covaris
plates, using the NEBNext® Ultra II kit (New England Biolabs) following the
manufacturer’s instructions. Briefly, we performed end repair and A-tailing in a
combined reaction per sample (plate) for 30 min at 20°C, followed by thermal
enzyme inactivation at 65°C for 30 min. We next ligated adaptors to the cDNA
templates using the NEBNext® ligation master mix plus enhancer and the TruSeq
unique dual indexed IDT adaptors (Illumina, Supplementary Data 2). We incu-
bated the ligation reactions for 15 min at 20°C. We purified the ligated sequencing
libraries using a Hamilton STAR NGS liquid handler, with two rounds of magnetic
SPRI bead purification (0.7× volume).
ILLUMINA sequencing. We pooled sequencing libraries (24–48 samples/pool) and
quantified the pools using the Qubit dsDNA assay (Thermo Fisher). Depending on
DNA concentration samples were diluted and denatured to a final loading con-
centration of 10 pM. We sequenced the pools using Illumina MiSeq sequencers
with 300-cycle MiSeq v2 reagent kits (Illumina). We used dual indexed paired-end
sequencing, this resulted in 150×8×8×150 bp cycles of data acquisition and ima-
ging. We performed basecalling in real-time using MCS v3.1 and generated FASTQ
files using MiSeq Reporter. For each run, we collected at least 15 M PE reads (>4.5
Gb) with base qualities of >Q30 for at least 90% of bases.
Viral concentration regression. We regressed the Ct values on sampling date
using the lm function in R. For replication, we fetched the Australian data set at
https://github.com/MDU-PHL/COVID19-paper/raw/master/VIC.csv, and regres-
sed the Ct values on the sampling date as with the Icelandic data. To be comparable
to the Icelandic data, we considered a subset where we excluded cases with Ct
values >37 and were detected prior to 2020/02/24. This had minimal impact on the
slope estimate, as the slope estimate was 1.04 cycle per week (95% CI: 0.72–1.36)
for the subset and 1.04 cycle per week (95% CI: 0.72–1.36) for the full set.
Alignment and variant calling. We aligned the sequences against the SARS-CoV-
2 reference genome (NC_045512.2)17 using bwa mem18. We marked possible PCR
duplicate with mark duplicates from Picard tools (version 1.117) and we excluded
reads with less than 50 bases aligned to reference from alignment. We called
sequence variants and genotyped them jointly across all the samples with a
modified version of Graphtyper19 and the following settings:
-no_filter_on_read_bias,-no_filter_on_strand_bias -no_filter_on_coverage
-impurity_threshold=1.0 -primer_bedpe= {primer_file} -is_only_cigar_discovery
-genotype_aln_min_support_ratio=0.30 -genotype_aln_min_support=5
-is_discovery_only_for_paired_reads -no_filter_on_begin_pos.
The modified version excluded the termini of reads overlapping a primer region
to avoid primer and template chimeras. To call a mutation per sample, we required
that Graphtyper called the alternative allele of the sequence variant in the sample.
Further, we required that 80% of the reads supported the alternative allele and at
least five reads supported the alternative or reference allele. If the sample did not
meet these criteria, we flagged the mutation per sample as failed. If the failed
fraction of samples per sequence variant exceeded 30% we did not consider the
sequence variant for further analysis.
Accumulation rate per time. We dichotomized the mutations into two categories
based on whether they were observed in the filtered GISAID data in 10 or more
copies and the sample carrying the mutation in GISAID was sampled before the
31st of March. The accession numbers of the filtered GISAID set are in Supple-
mentary Data 3. Per mutation subset, we regressed the number of mutations per
sample as a function of the sampling date. We modeled this with a generalized
linear model using Poisson and identity link. The modeling was implemented with
the glm function in R20. We restricted to the samples with coverage across most of
the genome, i.e., we excluded samples if the depth of coverage was strictly <5 reads
for 500 genomic sites after restricting to bases of quality 20 or higher.
Analysis of public data sets. A total of 11,133 of 17,039 SARS-CoV-2 sequences
available at the GISAID website on May 7th were used to estimate the accumulation of
mutations per unit of time. Only almost complete and high-quality sequences were used
in these analyses, where the first position was ≤200 and the last position was ≥29,750,
where the no >2% of nucleotides were reported as totally ambiguous (N), no more than
two positions were reported as partially ambiguous (Y, R, K, M, S, W, B, D, H, V) and
no more than five deletions were reported. The sequences from Icelandic hosts, pre-
viously deposited by deCODE Genetics, were also excluded to ensure independence
between the results based on deCODE sequences and those submitted to GISAID.
SIPR model. We constructed an epidemiological model using the ordinary dif-
ferential equations depicted in Supplementary Fig. 4. For the numerical solution of
the ordinary differential equations, we used the R-package deSolve. We solved the
differential equation using two epochs, one with an exponential growth phase and
then a containment phase. The S, I, P, and R values at the end of the exponential
growth phase were used as initial values in the containment phase. In the expo-
nential growth phase, the following parameters were used in the SIPR model:
initial susceptible population size (S0= 350000), initial infected population size
(I0= 100), infection rate (α= 0.197/ S0), and recovery rate (β= α/2). Then in the
containment phase, the alpha was decreased to model containment measures.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
The SARS-CoV-2 sequences used in this manuscript are available at GISAID and ENA
(PRJEB44803), the GISAID accession numbers are the following (with EPI_ISL prefix):
417481, 417535–417876, 424367–424624, 1585943–1585977, 1585979–1586097,
1586099–1586110, 1586112–1586121, 1586123, 1586125–1586178, 1586180–1586225,
1586227–1586267, 1586269–1586389, 1586391–1586416, 1586418–1586433,
1586435–1586438, 1586440–1586460, 1586463–1586490, 1586493–1586494,
1586496–1586571, 1586573–1586574, 1586576–1586589, 1586591–1586626,
1586628–1586636, 1586638–1586646, 1586648–1586662, 1586664–1586669,
1586671–1586777, 1586780–1586791, 1586793–1586809, 1586811–1586827,
1586829–1586846, 1586848–1586862, 1586864–1586883, 1586885–1586893. The consensus
sequences used for the comparative analysis are available at GISAID, the accession numbers
are supplied in Supplementary Data 3. Source data are provided with this paper.
Code availability
Bwa mem was used to align the short-read sequences against the SARS-CoV-2 reference.
Graphtyper was used to call sequence variants and for genotyping (version 2.3.0). Both
are publicly available. The code to fit the ordinary differential equations from the
epidemiological model is at https://github.com/hakon-jon/SARS-CoV-2-epi-model along
with regression examples.
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